Reducing Blood Loss During Cesarean Hysterectomy for Placenta Accreta Spectrum

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

August 1, 2021

Conditions
Cesarean Section Complications
Interventions
DRUG

intravenous tranexamic acid

1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy

DRUG

Topical tranexamic acid

2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.

DRUG

Normal saline

110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy

Trial Locations (1)

81528

AswanUH, Aswān

All Listed Sponsors
lead

Aswan University Hospital

OTHER

NCT03570710 - Reducing Blood Loss During Cesarean Hysterectomy for Placenta Accreta Spectrum | Biotech Hunter | Biotech Hunter